$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne I have been searching for small oncology companies with the potential to experience the kind of revaluation that occurs when convincing clinical data finally attracts market attention. **MAIA Biotechnology ($MAIA)** may be one of the more interesting examples I have found. MAIA currently trades around **$1.33**, giving it a market capitalization of approximately **$80 million** with 60.8 million shares outstanding. This remains a tiny valuation for a company that already has a randomized Phase 3 cancer trial underway. ([Current market data](https://ir.maiabiotech.com/stock-data/quote)) The entire thesis revolves around **ateganosine**, previously called THIO, a potentially first-in-class small molecule designed to attack cancer through telomeres while simultaneously activating an immune response. # What does ateganosine actually do? Telomeres protect the ends of chromosomes and help cancer cells continue dividing. Ateganosine is designed to be incorporated into the telomeres of telomerase-positive cancer cells, damaging those telomeres and causing cancer-cell death. The damaged telomeric material may also activate the cGAS/STING immune pathway and stimulate adaptive immune responses. In theory, this can turn a tumor that has stopped responding to checkpoint inhibitors back into one the immune system can recognize and attack. This mechanism is supported by peer-reviewed research. A 2020 *Cancer Cell* study found that 6-thio-dG produced telomere-associated DNA damage, activated STING-dependent antitumor immunity and improved responses to checkpoint inhibition in preclinical models. ([Cancer Cell study](https://pubmed.ncbi.nlm.nih.gov/32619407/)) A separate 2015 study found that 6-thio-dG produced rapid death in telomerase-positive cancer cells while having considerably less effect on normal telomerase-negative cells. ([AACR study](https://pubmed.ncbi.nlm.nih.gov/25516420/)) The goal is therefore bigger than simply adding another chemotherapy. MAIA is attempting to create an entirely new class of telomere-targeting immunotherapy that could potentially be combined with several existing checkpoint inhibitors. # The Phase 2 results are difficult to ignore MAIA’s THIO-101 Phase 2 study enrolled heavily pretreated patients with advanced non-small cell lung cancer, or NSCLC, whose cancers had already progressed after checkpoint inhibitors and chemotherapy. In Parts A and B, **22 third-line patients** who received at least one dose produced an estimated median overall survival of: * **17.8 months** * 95% confidence-interval lower bound of **12.5 months** * 99% confidence-interval lower bound of **10.8 months** Published studies cited by MAIA indicate approximately **five to six months** of median survival for chemotherapy in comparable third-line patients. That makes the observed 17.8 months close to three times the historical benchmark. ([Phase 2 survival update](https://ir.maiabiotech.com/news-events/press-releases/detail/138/maia-biotechnology-announces-positive-efficacy-update-for)) Eight patients from Parts A and B survived beyond two years without receiving another subsequent line of therapy, and one third-line patient had survived more than 33 months as of June 2026. ([Long-term survival update](https://ir.maiabiotech.com/news-events/press-releases/detail/180/maia-biotechnology-completes-international-enrollment-in)) Earlier results at the selected 180 mg dose also showed: * **38% objective response rate** * **85% disease-control rate** * **5.5 months median progression-free survival** * 78% survival at six months The important qualification is that the 38% response rate came from only **eight evaluable patients** at the selected dose. These are encouraging results, but the sample was small and the comparisons were against historical chemotherapy data rather than a randomized control arm. ([ASCO 2024 results](https://ir.maiabiotech.com/news-events/press-releases/detail/108/maia-biotechnology-reveals-new-clinical-data-showing)) MAIA has subsequently expanded the Phase 2 trial. Initial Part C results reported in July 2026 showed disease control in **19 of 21 evaluable patients**, equal to a **90.5% disease-control rate**. Every patient in this group had previously received docetaxel and had demonstrated resistance to immunotherapy and other chemotherapy. ([Part C expansion results](https://ir.maiabiotech.com/news-events/press-releases/detail/181/maia-biotechnology-reports-strong-initial-efficacy-data-in)) That does not prove the drug works. It does show that the original signal has continued appearing as additional patients have been treated. # The real test is now underway MAIA began its randomized Phase 3 THIO-104 trial in December 2025. The trial will enroll up to **300 patients** with advanced third-line NSCLC and randomize them 1:1 between: * Ateganosine followed by Regeneron’s checkpoint inhibitor Libtayo * Investigator-selected chemotherapy using docetaxel, gemcitabine or vinorelbine The primary endpoint is **overall survival**, with response rate, progression-free survival and duration of response included as secondary endpoints. ([THIO-104 Phase 3 design](https://maiabiotech.com/wp-content/uploads/2025/10/maia_thio-104_esmo_2025_tip.pdf)) As of June 2026, 29 patients had been dosed across 34 active sites in six countries. Management was targeting up to 100 enrolled patients by the end of 2026 and expects sufficient survival data for an interim analysis in 2027. ([Phase 3 enrollment update](https://ir.maiabiotech.com/news-events/press-releases/detail/177/maia-biotechnology-reports-strong-enrollment-and-dosing)) This randomized trial is the key. If ateganosine produces anything close to the 17.8-month Phase 2 survival result against a concurrent chemotherapy control, an $80 million valuation would be difficult to reconcile with the drug’s commercial potential. The FDA has already granted ateganosine **Fast Track designation** for third-line NSCLC. Fast Track allows more frequent FDA interaction and can potentially support rolling review or priority review, although it does not guarantee approval. ([FDA Fast Track announcement](https://ir.maiabiotech.com/news-events/press-releases/detail/146/maia-biotechnology-receives-fdas-fast-track-designation)) # This is a very large market Lung cancer remains the leading cause of cancer death worldwide, with approximately **2.5 million new cases and 1.8 million deaths in 2022**. ([World Health Organization](https://www.who.int/news-room/fact-sheets/detail/lung-cancer)) Approximately **80% to 85% of lung cancers are NSCLC**. ([American Cancer Society](https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html)) Third-line NSCLC is only part of this total market, so it would be misleading to treat the entire NSCLC market as MAIA’s immediately addressable opportunity. However, the broader commercial market is enormous. Grand View Research estimates that the worldwide NSCLC therapeutics market will grow from approximately **$27.1 billion in 2026 to $63.5 billion by 2033**. ([NSCLC market research](https://www.grandviewresearch.com/industry-analysis/non-small-cell-lung-cancer-nsclc-therapeutics-market)) More significantly, there remains no universally accepted third-line standard after patients have failed both chemotherapy and checkpoint inhibition. ([Peer-reviewed review of third-line NSCLC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8797454/)) Even a modest share of this treatment population could support annual revenue many times MAIA’s present market capitalization. Success in NSCLC could also validate the platform for other telomerase-positive cancers. # The large-pharma relationships are real MAIA has clinical-supply relationships with three major oncology companies: # Regeneron Regeneron supplies **Libtayo**, or cemiplimab, for THIO-101. The agreement was expanded in December 2024 to cover the Phase 2 expansion. MAIA sponsors the study and retains its worldwide commercial rights to ateganosine. ([Regeneron agreement](https://ir.maiabiotech.com/news-events/press-releases/detail/118/maia-biotechnology-announces-expansion-of-clinical-supply)) # BeOne Medicines, formerly BeiGene BeOne agreed to supply **tislelizumab** for planned studies combining it with ateganosine in hepatocellular carcinoma, small-cell lung cancer and colorectal cancer. ([BeOne agreement](https://ir.maiabiotech.com/news-events/press-releases/detail/122/maia-biotechnology-announces-clinical-supply-agreement-with)) # Roche MAIA entered a master clinical-supply agreement with Roche covering future studies of ateganosine followed by Roche’s checkpoint inhibitor **Tecentriq**, or atezolizumab, in difficult-to-treat cancers. ([Roche agreement](https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply)) These are supply collaborations, not licensing transactions or buyout agreements. MAIA still pays for its clinical trials. However, having Regeneron, Roche and BeOne provide their checkpoint inhibitors reduces trial costs and allows ateganosine to be tested with several commercially established immunotherapies. It also preserves strategic flexibility because MAIA controls the worldwide development and commercialization rights to ateganosine. # Insiders are putting in their own money The insider buying is one of the more interesting parts of this story. In November 2025, CEO Vlad Vitoc and directors Cristian Luput and Stan Smith purchased approximately **182,445 shares in open-market transactions** at an average price of approximately $1.06. Vitoc personally purchased 94,300 shares at an average of $1.08. ([November insider purchases](https://ir.maiabiotech.com/news-events/press-releases/detail/159/maia-biotechnology-announces-open-market-purchases-by-ceo)) In June 2026: * CEO Vlad Vitoc purchased another **72,700 shares** at an average of approximately **$1.39**, spending roughly $101,000. * Director Stan Smith purchased **75,000 shares** at approximately **$1.34**, spending roughly $100,000. ([June insider purchases](https://ir.maiabiotech.com/news-events/press-releases/detail/175/maia-biotechnology-announces-open-market-purchases-by-ceo)) That represents approximately **330,000 open-market shares and nearly $400,000 invested by leadership** across those two disclosed rounds. MAIA’s 2026 proxy also reported that Vitoc beneficially owned approximately **4.14 million shares and exercisable securities**, equal to 6.5% of the company at that time. ([2026 proxy statement](https://ir.maiabiotech.com/sec-filings/all-sec-filings/content/0001140361-26-013499/ny20065433x1_def14a.htm)) Insider buying cannot validate a clinical trial, but repeated open-market purchases are more meaningful than executives simply receiving stock options as compensation. # The CEO has relevant oncology experience Founder and CEO **Dr. Vlad Vitoc** is a physician with an MBA and more than 25 years of pharmaceutical and biotechnology experience. Before MAIA, he held leadership roles at Bayer, Astellas, Cephalon and Incyte. His experience includes the development or commercialization of major oncology drugs, and MAIA’s broader leadership team has worked on drugs including Tarceva, Nexavar, Xtandi, Treanda and Zometa. ([MAIA 2025 annual report](https://ir.maiabiotech.com/sec-filings/all-sec-filings/content/0001493152-26-015458/formars.pdf)) Vitoc’s stated vision is to establish telomere targeting as a new cancer-treatment platform rather than develop ateganosine for only one narrow indication. MAIA is initially pursuing third-line NSCLC because the unmet need is high and the regulatory path is relatively clear, but the company is also exploring liver cancer, small-cell lung cancer, colorectal cancer and pediatric brain cancer. The National Cancer Institute awarded MAIA a **$2.3 million grant** supporting the U.S. expansion of THIO-101, providing another external scientific review of the program. ([NCI grant announcement](https://ir.maiabiotech.com/news-events/press-releases/detail/151/maia-biotechnology-awarded-2-3-million-grant-by-national)) # Balance sheet and valuation MAIA reported: * **$27.6 million in cash** at June 30, 2026 * Approximately **$12.1 million of operating cash burn** during the first six months of 2026 * 60.8 million shares outstanding * No product revenue The company raised approximately $33 million gross in March 2026 by selling 22 million shares at $1.50. Management says those proceeds are expected to fully fund the ongoing Phase 3 trial. ([MAIA Q2 2026 SEC filing](https://www.sec.gov/Archives/edgar/data/1878313/000149315226036764/form10-q.htm)) The financing substantially improved MAIA’s balance sheet, but it also increased the outstanding share count from 38.6 million at the end of 2025 to 60.8 million by June 2026. That dilution is real and needs to be included in any valuation. At approximately $80 million, the market is assigning only about $52 million of value above MAIA’s June cash balance to the clinical program, management team, intellectual property and pharma collaborations. # What could go wrong? This remains an extremely speculative biotechnology investment. The biggest risks are: 1. **The strongest survival data comes from only 22 third-line patients.** 2. **THIO-101 was not randomized**, so comparisons with historical chemotherapy results can be distorted by differences in patient selection. 3. The earlier 38% response rate came from only eight evaluable patients at the selected dose. 4. The randomized Phase 3 results may fail to reproduce the Phase 2 signal. 5. MAIA has no commercial products or revenue and may eventually require additional capital. 6. There are approximately **13.1 million outstanding warrants and 16.7 million stock options**, creating potential future dilution. 7. The Regeneron, Roche and BeOne relationships are supply agreements, not commitments to acquire or license ateganosine. 8. A recently filed $150 million shelf registration creates additional financing flexibility but also a potential dilution overhang. # My thesis I do not think MAIA currently has the most proven data in small-cap oncology. Its Phase 2 study was too small and lacked a randomized control. What MAIA may have is one of the more asymmetric setups: * Approximately **$80 million market cap** * A first-in-class mechanism supported by published science * **17.8-month median survival** in a population historically surviving approximately five to six months * **90.5% disease control** in the initial Phase 2 expansion cohort * A randomized, 300-patient Phase 3 trial already underway * FDA Fast Track designation * Clinical-supply relationships with Regeneron, Roche and BeOne * Repeated open-market purchases by the CEO and directors * Cash that management expects will fund the Phase 3 trial * Interim Phase 3 data anticipated in 2027 The Phase 3 trial will determine whether this is a breakthrough or simply another encouraging small, single-arm oncology study that fails when tested against a proper control. If Phase 3 survival lands anywhere near the Phase 2 result, I believe the company would be worth many multiples of its current valuation and would become an obvious licensing or acquisition candidate. If the survival advantage disappears in the randomized trial, the downside could be severe because nearly the entire valuation depends on ateganosine. That is the bet: **an approximately $80 million company attempting to prove that it can nearly triple survival in one of the most difficult areas of lung cancer treatment.**